



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/623,728

01/22/2001

Habib Zaghouni

8114-005-WO-CIP.2-US

6688

32301 7590 05/27/2008
CATALYST LAW GROUP, APC
9710 SCRANTON ROAD, SUITE S-170
SAN DIEGO, CA 92121

EXAMINER

SZPERKA, MICHAEL EDWARD

ART UNIT

PAPER NUMBER

1644

MAIL DATE

DELIVERY MODE

05/27/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address : COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
09623728	1/22/01	ZAGHOUBANI, HABIB	8114-005-WO-CIP.2-US

CATALYST LAW GROUP, APC
9710 SCRANTON ROAD, SUITE S-170
SAN DIEGO, CA 92121

EXAMINER

MICHAEL SZPERKA

ART UNIT	PAPER
----------	-------

1644	20080521
------	----------

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Upon review of the response and amendments received February 8, 2008 the following matter was observed: Applicant has amended claims to recite SEQ ID NO:1 and SEQ ID NO:2. However, no sequence listing, or disclosure of SEQ ID NOs: 1 and 2 appear to be in the application as filed. Applicant is reminded that the requirements of applications which contain sequence disclosures that include nucleotide and/or amino acid sequences are set forth in 37 CFR 1.821-1.825. Applicant is further reminded that if the instant application does not have an appropriate SEQ ID NO: for each disclosed sequence, then Applicant must comply with the Sequence Rules as set forth in 37 CFR 1.821-1.825. The instant specification does not appear to disclose SEQ ID NOs:1 or 2 in any figure or table and no sequence listing has been provided. As such, it appears that the instant application does not satisfy the requirements set forth in 37 CFR 1.821-1.825. Appropriate correction to comply with the rules is required. See attached Notice to Comply.

Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Szperka whose telephone number is 571-272-2934. The examiner can normally be reached on M-F 8:00-4:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eileen O'Hara can be reached on 571-272-0878. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Michael Szperka, Ph.D./
Patent Examiner, Art Unit 1644